Eastgate Biotech Corp.
ETBI · OTC
9/30/2017 | 6/30/2017 | 3/31/2017 | 12/31/2016 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.01 | 1.11 | -0.08 |
| FCF Yield | -108.80% | -14.26% | -0.89% | -1.73% |
| EV / EBITDA | -2.50 | 0.00 | -16.94 | -12.92 |
| Quality | ||||
| ROIC | 75.14% | 28.80% | 29.51% | 24.04% |
| Gross Margin | -299.12% | 50.28% | 0.00% | 85.07% |
| Cash Conversion Ratio | 0.84 | 0.18 | 0.13 | 0.18 |
| Growth | ||||
| Revenue 3-Year CAGR | -30.56% | -27.12% | – | -100.00% |
| Free Cash Flow Growth | -915.45% | -7.87% | 27.84% | -56.69% |
| Safety | ||||
| Net Debt / EBITDA | -1.79 | 0.00 | -1.99 | -1.98 |
| Interest Coverage | 0.00 | -2.18 | -24.44 | -16.43 |
| Efficiency | ||||
| Inventory Turnover | 0.82 | -0.07 | 0.00 | 0.00 |
| Cash Conversion Cycle | -415.31 | -1,421.37 | 0.00 | 1,802.76 |